Recipharm launches serialisation showcase line
Recipharm, the contract development and manufacturing organisation (CDMO), has launched a showcase line for serialisation, offering pharmaceutical companies the chance to view and trial its solution to the new European and US regulations.
The CDMO’s showcase line at Recipharm in Fontaine, France, is now operational and ready to demonstrate the company’s new standard solution for serialisation to customers. The showcase line will perform activities including the downloading of serial numbers from our Level 4 solution, serialisation of the package and the application of tamper evidence labels. It will also demonstrate manual aggregation including labelling of boxes and pallets and post-serialisation work, including the reworking and uploading of data to Level 4.
Recipharm’s new line is the latest step in a €40 million project to implement a state-of-the-art solution for its customers’ serialisation requirements across its 75 production lines in Europe.
The project, which is being carried out over the next three years, will ensure that all pharmaceutical companies using Recipharm’s contract manufacturing services comply with the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation, which makes the serialisation of licensed drug products in Europe a legal requirement from 2019.
As part of the serialisation roll-out, the CDMO has developed a unique pricing model which spreads the cost of the process across each customer’s ongoing supply agreement, removing the need to make any upfront investment.
From early 2017, Recipharm will offer the service free of charge until it becomes a legal requirement, allowing customers to overcome any challenges, determine their individual requirements and request any customisation before the deadline passes.
The CDMO’s company-wide serialisation project is being led by Staffan Widengren, director corporate projects at Recipharm. He said: “Having already provided serialised products in markets including Turkey, Korea and China we understand the complexity of implementing serialisation processes across existing production lines, so we made the decision very early on to be proactive and get ready for the changes as soon as we could.
“Companies that delay their preparations face a high risk of disruption to their production when the changes come into effect in 2019. By introducing this showcase line so far in advance we’ll be able to overcome any hurdles prior to the deadline and make the transition to serialised products as seamless as possible for our customers.
“As part of our preparations we’ve listened to our customers concerns surrounding serialisation, which is why we’ve introduced a unique pricing model to help improve the affordability of the process.”
The industry-wide serialisation, aggregation and verification directive is expected to improve traceability of drugs and help in the fight against counterfeit products entering the supply chain via the introduction of 2D barcodes on all saleable drug items and will ultimately improve patient safety.
Recipharm serves 250+ customers and expects 85% of its production to require serialisation. The CDMO will also be ready for US serialisation from November 2017 in-line with the US Drug Supply Chain Security Act (DSCSA).
Kjell Johansson, President Manufacturing Services Europe, email@example.com, +46 739 622 620
Staffan Widengren, Director Corporate Projects, firstname.lastname@example.org, +46 708 205280708 205280
For media enquiries, please contact Lindsay Baldry at ramarketing: email@example.com,
+44 191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Serialisation is a means to trace and track pharmaceuticals from manufacture through to prescription, using bar codes to record information about product origin, shelf life and batch. This will help the fight against counterfeit products entering the supply chain and ultimately improve patient safety.
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03